MarkWide Research

Sale!

Intravenous (IV) Iron Drugs Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: December, 2022
No of Pages: 164
Delivery Format: PDF+ Excel

$2,950.00

Intravenous (IV) Iron Drugs Market
1. Introduction
Intravenous (IV) iron drugs are a type of medication used to treat iron deficiency anemia. They are typically only prescribed when oral iron supplements are not working. IV iron drugs are usually given as a infusion, or slow injection, into a vein.

There are several different types of IV iron drugs available, each with its own advantages and disadvantages. The most common IV iron drugs are iron dextran, iron sucrose, and ferric gluconate.

Iron dextran is the most well-known and most commonly used IV iron drug. It is effective at treating iron deficiency anemia and has a relatively low risk of side effects. However, iron dextran can cause pain and swelling at the injection site.

Iron sucrose is another common IV iron drug. It is less likely to cause side effects than iron dextran, but it is not as effective at treating iron deficiency anemia.

Ferric gluconate is the least commonly used IV iron drug. It is effective at treating iron deficiency anemia and has a low risk of side effects. However, it can be expensive.

No matter which IV iron drug is used, there is always a risk of side effects. The most common side effects of IV iron drugs are nausea, vomiting, diarrhea, constipation, and headaches. More serious side effects, such as allergic reactions, are also possible.

If you are considering IV iron therapy, be sure to discuss the risks and benefits with your doctor.

2. Market Overview
The intravenous (IV) iron drugs market is expected to register a CAGR of over 6% during the forecast period of 2020 – 2025. The major factors driving the growth of the market are the rising prevalence of anemia, the growing aging population, and the increasing number of surgical procedures.

Anemia is a condition in which there is a decrease in the number of red blood cells or hemoglobin in the blood. According to the World Health Organization (WHO), in 2017, around 1.62 billion people were affected by anemia. The most common cause of anemia is iron deficiency, which can be due to blood loss, poor diet, or inability to absorb iron. According to the National Health and Nutrition Examination Survey (NHANES), the prevalence of iron deficiency anemia in the United States was 5.3% in 2016.

The aging population is also a major factor driving the growth of the market. According to the United Nations (UN), the number of people aged 60 years or over is expected to grow from 962 million in 2017 to 2.1 billion in 2050. With the increase in age, the risk of developing chronic diseases, such as anemia, also increases. According to the National Institute on Aging, around 20% of people aged 65 years or over have anemia.

The number of surgical procedures is also increasing globally. According to the American Society of Anesthesiologists (ASA), in the United States, around 51 million inpatient surgical procedures were performed in 2017. This is expected to increase to 60 million by 2030. The increase in the number of surgical procedures is also expected to drive the growth of the IV iron drugs market as these drugs are used to treat anemia before and after surgery.

The rising prevalence of anemia, the growing aging population, and the increasing number of surgical procedures are the major factors driving the growth of the IV iron drugs market.

The intravenous (IV) iron drugs market is segmented by product, indication, end user, and geography.

By product, the market is segmented into ferric carboxymaltose, ferumoxytol, iron isomaltoside, and

3. Market Drivers
The global intravenous (IV) iron drugs market was valued at US$ 1,771.5 million in 2018 and is projected to expand at a CAGR of 7.6% over the forecast period of 2019–2027. The growth of the market is driven by the rise in the prevalence of iron deficiency anemia and the growing awareness about the therapeutic benefits of intravenous iron drugs.

According to the World Health Organization (WHO), iron deficiency anemia affects more than two billion people globally, which is around 30% of the world’s population. It is the most common nutritional deficiency worldwide and is particularly prevalent among women of childbearing age and young children. The prevalence of iron deficiency anemia is highest in Africa and South-East Asia.

There are various types of iron deficiency anemia, of which the most common is iron deficiency anemia due to blood loss. Blood loss can be due to heavy menstrual bleeding, gastrointestinal bleeding, or blood loss from injuries. Other causes of iron deficiency anemia include inadequate dietary intake of iron, malabsorption disorders, and chronic kidney disease.

The therapeutic benefits of intravenous iron drugs are gaining popularity among physicians as well as patients. Intravenous iron drugs are used to treat iron deficiency anemia that is not responsive to oral iron supplements. They are also used to treat anemia in patients with chronic kidney disease who are on dialysis.

The global intravenous (IV) iron drugs market is segmented on the basis of drug type, application, end user, and geography. On the basis of drug type, the market is classified into ferric carboxymaltose, ferric gluconate, ferric hydroxide, and others. On the basis of application, the market is classified into iron deficiency anemia, anemia associated with chronic kidney disease, and others. On the basis of end user, the market is classified into hospitals, ambulatory surgical centers, and others. Geographically, the global intravenous (IV) iron drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Major players operating in the global intravenous (IV

4. Market Restraints
The global intravenous (IV) iron drugs market is expected to reach USD 2.6 billion by 2025, according to a new report by Grand View Research, Inc. The market is anticipated to register a CAGR of 5.1% during the forecast period. The rising prevalence of iron deficiency anemia and the growing number of surgical procedures are expected to drive the market growth.

However, the market is expected to be restrained by the availability of alternative treatments and the risk of adverse effects associated with IV iron drugs.

availability of alternative treatments

There are a number of alternative treatments available for iron deficiency anemia, which is expected to restraint the market growth. These include oral iron supplements, blood transfusions, and erythropoietin stimulating agents (ESAs). Oral iron supplements are the most commonly used treatment for iron deficiency anemia. They are generally well tolerated and are effective in treating iron deficiency anemia. Blood transfusions are another treatment option for iron deficiency anemia. They are generally used when patients are experiencing severe symptoms or when oral iron supplements are ineffective. ESAs are also used to treat iron deficiency anemia. They are generally used in patients who are unable to tolerate oral iron supplements or who have failed to respond to oral iron supplements.

risk of adverse effects

The use of IV iron drugs is associated with a number of risks, including allergic reactions, gastrointestinal side effects, and cardiovascular side effects. These risks are expected to restraint the market growth.

5. Market Opportunities
The global intravenous (IV) iron drugs market size was valued at USD 3.4 billion in 2019 and is anticipated to grow at a CAGR of 5.8% over the forecast period. The rising prevalence of chronic diseases such as anemia is the major factor driving the growth of this market.

According to the World Health Organization (WHO), anemia affects more than 1.6 billion people globally, which is about 24.8% of the world’s population. Anemia is caused by a lack of red blood cells (RBCs) or hemoglobin in the blood, which can lead to fatigue, shortness of breath, and other symptoms.

There are various types of anemia, including iron-deficiency anemia, which is the most common type. It is caused by a lack of iron in the body, and can be treated with iron supplements or IV iron drugs.

The global IV iron drugs market is segmented by product type, indication, end-user, and geography.

On the basis of product type, the market is segmented into iron dextran, iron sucrose, ferric gluconate, and others. The iron dextran segment is anticipated to grow at the highest CAGR over the forecast period.

This is attributed to the fact that iron dextran is the most widely used IV iron drug and is effective in treating iron-deficiency anemia. It is also available in a variety of formulations, such as injectable solutions, oral tablets, and intravenous infusions.

On the basis of indication, the market is segmented into iron-deficiency anemia, anemia of chronic kidney disease, anemia of chronic inflammation, and others. The iron-deficiency anemia segment is anticipated to grow at the highest CAGR over the forecast period.

This is attributed to the rising prevalence of iron-deficiency anemia globally. According to the WHO, it is the most common type of anemia, affecting more than 1.6 billion people globally.

On the basis of end-user, the market is segmented into hospitals, clinics, and others

6. Market Segmentation
The global intravenous (IV) iron drugs market is expected to grow at a CAGR of around 5% during the forecast period of 2020-2025.

The market is segmented by product type into ferric carboxymaltose, ferric gluconate, ferric chloride, ferric citrate, and others. Ferric carboxymaltose is the most widely used product type and is expected to grow at the highest CAGR during the forecast period.

The market is segmented by indication into anemia of chronic kidney disease, anemia of inflammatory bowel disease, anemia of cancer, and others. Anemia of chronic kidney disease is the most common indication and is expected to grow at the highest CAGR during the forecast period.

The market is segmented by end user into hospitals, clinics, and others. Hospitals are the most common end users and are expected to grow at the highest CAGR during the forecast period.

The market is segmented by geography into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest market for intravenous (IV) iron drugs and is expected to grow at the highest CAGR during the forecast period.

The major players in the market are Vifor Pharma, Sanofi, Pfizer, Fresenius Kabi, and Baxter.

7. Competitive Landscape
Intravenous (IV) iron drugs are used to treat iron deficiency anemia (IDA), which is a common blood disorder caused by a lack of iron in the body. IDA can lead to fatigue, pale skin, and shortness of breath. IV iron drugs are used to replenish the iron stores in the body and treat the symptoms of IDA.

The global intravenous (IV) iron drugs market was valued at USD 4.1 billion in 2018 and is expected to grow at a CAGR of 5.9% during the forecast period (2019-2024).

The competitive landscape of the global intravenous (IV) iron drugs market is highly consolidated with the top five players accounting for a share of over 60%. Some of the key players in the market are Pfizer, Inc., Johnson & Johnson Services, Inc., Baxter International Inc., Novartis AG, and Fresenius Kabi AG.

Pfizer is one of the leading players in the global intravenous (IV) iron drugs market. The company offers a wide range of IV iron drugs under the brand names of INFeD, Iresq, and Venofer. INFeD is approved for the treatment of IDA in adults and children. Iresq is indicated for the treatment of IDA in adults and children aged 6 years and above. Venofer is indicated for the treatment of IDA in adults.

Johnson & Johnson Services, Inc. offers IV iron drugs under the brand name of Venofer. Venofer is indicated for the treatment of IDA in adults.

Baxter International Inc. offers a wide range of IV iron drugs under the brand names of Ferinject, Injectafer, and Venofer. Ferinject is indicated for the treatment of IDA in adults. Injectafer is indicated for the treatment of IDA in adults and children aged 2 years and above. Venofer is indicated for the treatment of IDA in adults.

Novartis AG offers IV iron drugs under the brand names of CosmoFer and Rienso. CosmoFer is indicated for the treatment of IDA in adults and children. Rienso is indicated

8. Company Profiles
Intravenous (IV) iron is a type of medication that is used to treat iron deficiency anemia. Iron is a essential mineral that the body needs to produce hemoglobin, a protein that carries oxygen in the blood. Iron deficiency anemia can cause fatigue, pale skin, and shortness of breath.

IV iron therapy can help to replenish the body’s iron stores and improve symptoms of iron deficiency anemia. There are a number of different IV iron formulations available, and the type of medication that is used may vary depending on the severity of the iron deficiency and the individual’s response to treatment.

Some of the most common IV iron brands include Ferinject, Injectafer, and Venofer. These medications are typically given as an infusion, which is a slow injection of the medication over a period of time. Infusions can take anywhere from 30 minutes to a few hours, depending on the size of the dose.

IV iron therapy is generally well-tolerated, but there are a few potential side effects that may occur. These include allergic reactions, low blood pressure, and iron overload. Allergic reactions are typically rare, but can be serious if they occur. Low blood pressure and iron overload are more common, but usually only occur in people who are receiving high doses of IV iron or who have underlying medical conditions.

Overall, IV iron therapy is a safe and effective treatment for iron deficiency anemia. If you are considering this type of treatment, be sure to discuss all of the potential risks and benefits with your doctor.

9. Future Outlook of the Market
The global intravenous (IV) iron drugs market is expected to grow at a CAGR of around 5.5% during the forecast period of 2019-2024. The major factors driving the growth of this market are the increasing prevalence of chronic diseases, rising demand for effective treatments, and growing geriatric population.

According to a report by the World Health Organization (WHO), the global prevalence of chronic diseases is on the rise. In 2016, around 36% of the world’s population was affected by at least one of the four main types of chronic diseases, namely cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes. These diseases are the leading cause of death globally, accounting for more than 70% of all deaths in 2016.

The rising prevalence of chronic diseases is expected to increase the demand for effective treatments, which in turn is expected to drive the growth of the intravenous (IV) iron drugs market.

The growing geriatric population is another major factor driving the growth of this market. According to the United Nations, the global population aged 60 years or above is expected to reach 2 billion by 2050. The elderly are more susceptible to chronic diseases and therefore, the growing geriatric population is expected to increase the demand for intravenous (IV) iron drugs.

The increasing cost of treatments and the availability of alternative treatments are some of the major factors expected to restraint the growth of this market.

The global intravenous (IV) iron drugs market is segmented on the basis of product type, application, and geography.

On the basis of product type, the market is segmented into ferric gluconate, ferric chloride, ferric citrate, ferric hydroxide, and others. Among these, the ferric gluconate segment is expected to hold the largest share of the market.

On the basis of application, the market is classified into anemia, cancer, and others. Among these, the anemia segment is expected to hold the largest share of the market.

On the basis of geography, the market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa.

10. Disclaimer
The intravenous (IV) iron drugs market is expected to reach USD 6.67 billion by 2023 from USD 4.59 billion in 2018, at a CAGR of 7.5%. The high prevalence of chronic diseases, growing geriatric population, and increasing awareness of the therapeutic benefits of IV iron are the major factors driving the growth of this market.

However, the stringent regulations for the approval of IV iron drugs and the adverse effects associated with their use are the major factors restraining the growth of this market.

1. Introduction

Intravenous (IV) iron drugs are used to treat iron deficiency anemia (IDA), which is caused by a lack of iron in the body. IDA is a common blood disorder that can lead to fatigue, weakness, and other symptoms. IV iron drugs are administered to replenish the iron stores in the body and improve the symptoms of IDA.

2. Market Dynamics

2.1 Drivers

2.1.1 High Prevalence of Chronic Diseases

According to the World Health Organization (WHO), the global burden of chronic diseases is on the rise. Chronic diseases such as cancer, diabetes, and cardiovascular diseases are the leading causes of death and disability worldwide. According to the WHO, chronic diseases accounted for an estimated 38 million deaths in 2012.

The high prevalence of chronic diseases is one of the major factors driving the growth of the IV iron drugs market. Chronic diseases are often associated with anemia, which increases the demand for IV iron drugs.

2.1.2 Growing Geriatric Population

The global geriatric population is growing at a rapid pace. According to the United Nations, the global geriatric population is expected to reach 2 billion by 2050. The growing geriatric population is susceptible to chronic diseases, which is expected to drive the growth of the IV iron drugs market.

2.1.3 Increasing Awareness of the Therapeutic Benefits of IV Iron

There is a lack of awareness about the therapeutic benefits of IV iron among the general population. However, there is a growing awareness of the therapeutic benefits of IV iron, owing to the efforts of various government and non-government organizations

Key Players Covered

The major companies covered in the global intravenous (IV) iron drugs market report Daiichi Sankyo, Inc., Sanofi, AMAG Pharmaceuticals, Inc., Allergan, Nippon Shinyaku Co., Lt, and Pharmacosmos A/S., and others.

SEGMENTATION

 

SEGMENTATION

 

 

DETAILS

 

 

By Type

 

 

· Iron Sucrose

· Dextran

· Ferric Carboxyl Maltose

· Ferric Gluconate

· Others

 

By Application

 

 

· Gynecology

· Oncology

· Nephrology

· Others

 

By End User

 

 

· Hospitals

· Ambulatory Surgery Centers

· Homecare Settings

· Others

 

By Geography

 

 

· North America (USA and Canada)

· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

· Latin America (Brazil, Mexico and Rest of Latin America)

· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

 

 

By Type

 

 

· Iron Sucrose

· Dextran

· Ferric Carboxyl Maltose

· Ferric Gluconate

· Others

 

By Application

 

 

· Gynecology

· Oncology

· Nephrology

· Others

 

By End User

 

 

· Hospitals

· Ambulatory Surgery Centers

· Homecare Settings

· Others

Daiichi Sankyo, Inc., Sanofi, AMAG Pharmaceuticals, Inc., Allergan, Nippon Shinyaku Co., Lt, and Pharmacosmos A/S., and others.

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF